Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL115366 | 0.83 | DYRK1A (0.58) | DYRK1AKMT2ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL29361664 | 0.83 | DYRK1A (0.58) | DYRK1AKMT2ASMN1; SMN2KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL28263323 | 0.81 | DYRK1A (0.56) | DYRK1AKMT2ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL28180691 | 0.80 | DYRK1A (0.41) | DYRK1AKMT2ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL24425916 | 0.77 | DYRK1A (0.72) | DYRK1AKMT2ASMN1; SMN2ALDH1A1MEN1 | |
| Benzo[D]Oxazole SCHEMBL28373722 | 0.77 | NPC1 (0.46) | DYRK1AKMT2ASMN1; SMN2KDM4EMAPT | |
| Hydrazine SCHEMBL27569854 | 0.75 | DYRK1A (0.50) | DYRK1AKMT2ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL926971 | 0.74 | DYRK1A (0.49) | DYRK1AKMT2ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL1798498 | 0.74 | DYRK1A (0.49) | DYRK1AKMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3092188 | 0.74 | DYRK1A (0.49) | DYRK1AKMT2ASMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955769-B | Gold-based catalyst for polyvinyl chloride production and preparation method and application thereof | 南开大学 | 2025-01-10 | — | — | CN | claimed |
| CN-118955769-A | Gold-based catalyst for polyvinyl chloride production and preparation method and application thereof | 南开大学 | 2024-11-15 | — | — | CN | claimed |
| CN-115368255-B | Anthraquinone diamine monomer, cyan intrinsic polyimide derived from anthraquinone diamine monomer and preparation method of cyan intrinsic polyimide | 上海交通大学 | 2024-06-25 | — | — | CN | claimed |
| CN-117534834-A | Polymer, preparation method and application thereof, and intrinsic low-temperature curing negative photoresist | 上海交通大学 | 2024-02-09 | — | — | CN | claimed |
| CN-112384546-B | Thermally conductive resin composition | 东洋纺株式会社 | 2024-01-16 | — | — | CN | claimed |
| CN-116874885-A | Polyarylether grafted carbon nano tube containing heterocyclic structure and continuous fiber reinforced thermoplastic resin matrix composite material thereof | 大连理工大学 | 2023-10-13 | — | — | CN | claimed |
| CN-116836384-A | Polymer for black matrix, preparation method and application thereof | 上海交通大学 | 2023-10-03 | — | — | CN | claimed |
| CN-115197082-B | Anthraquinone diamine monomer, magenta intrinsic polyimide derived from anthraquinone diamine monomer and preparation method of magenta intrinsic polyimide | 上海交通大学 | 2023-09-22 | — | — | CN | claimed |
| CN-115232303-B | Polymer for black matrix, preparation method and application thereof | 上海交通大学 | 2023-09-15 | — | — | CN | claimed |
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4737445-A1 | NOVEL SATURATED HETEROCYCLE-SUBSTITUTED HETEROARYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2026-05-06 | — | — | EP | disclosed |
| US-20260103446-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4702026-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4019501-B1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20050101604-A1 | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of bruton's tyrosine kinase by such compounds | GILEAD CONNECTICUT, INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005005429-A1 | CERTAIN HETEROCYCLIC SUBSTITUTED IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHODS OF INHIBITION OF BRUTON’S TYROSINE KINASE BY SUCH COMPOUNDS | CELLULAR GENOMICS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| US-5057526-A | Immunological disorders, suppress organ rejection | BOEHRINGER MANNHEIM GMBH (DE) | 1991-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | CD38, BCL9, BCL6B | DYRK1A 2437/4885KMT2A 2357/4885SMN1; SMN2 2466/4885 |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | DYRK1A 1421/4885KMT2A 3770/4885SMN1; SMN2 2292/4885 |
| US-20050101604-A1 | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of bruton's tyrosine kinase by such compounds | BTK, SYK, LYN | DYRK1A 400/4885KMT2A 733/4885SMN1; SMN2 1459/4885 |
| US-20260103446-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | CFTR, CLCN2, SLC26A3 | DYRK1A 1109/4885KMT2A 4408/4885SMN1; SMN2 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.